Leucemia limfocitară cronică

Objectives

The national clinical protocol for chronic lymphocytic leukaemia, coded C91.1, provides an evidence-informed framework for diagnosis, treatment, follow-up, management of complications, rehabilitation and institutional adaptation across Moldova’s health service. It aims to improve early and primary diagnosis, optimise treatment during clinically and haematologically active disease, achieve durable complete clinical-haematological remission or prolonged survival, reduce disability and recurrence, and support physical and social reintegration.[1][2][3][4][5]

• Improve diagnostic confirmation through clinical assessment, blood-count analysis, bone-marrow examination, immunophenotyping, differential diagnosis and selected cytogenetic testing.[6][7][8]
• Reduce lymphoid-cell proliferation and lymph-node, splenic and hepatic enlargement, while achieving remission or prolonging survival according to disease stage, form and prognostic profile.[9][10][11]
• Detect relapse and complications early through dynamic clinical and haematological follow-up.[6][12][13]
• Manage infectious, autoimmune, anaemic and haemorrhagic complications, including through supportive medicines and blood-component therapy where indicated.[14][15][16]
• Support informed, respectful and preference-sensitive care by discussing investigations and treatment options with patients and providing accessible information to patients and families.[17][8]
• Recognise that primary prevention is not undertaken because the cause of chronic lymphocytic leukaemia is unknown; secondary prevention focuses on follow-up and early identification of recurrence.[18][6]

Implementation

Implementation combines tiered service delivery, specialist-led clinical decision-making, standardised diagnostic and treatment pathways, specified workforce and infrastructure requirements, and clinical monitoring and audit. Care may be provided in primary care, specialised outpatient services, day hospitals and inpatient haematology units, with referral to a haematologist for suspected cases and treatment planning based on disease stage, progression, complications, genetic risk, comorbidity and treatment tolerance.[1][3][9][11]

• Deliver initial assessment in primary care through history-taking, examination, full blood count with platelets and reticulocytes, differential diagnosis, referral of suspected cases to haematology, and assessment of hospitalisation need.[18]
• Confirm and stratify disease through blood and marrow investigations, flow-cytometry immunophenotyping, prognostic markers, and cytogenetic testing for abnormalities including del(17p), del(11q), trisomy 12, del(13q) and TP53 mutation when clinically indicated.[19][20][21]
• Provide observation with regular clinical and haematological review for appropriate early-stage disease, and initiate systemic therapy where symptoms, progressive cytopenias, significant tumour burden, recurrent infection, rapid lymphocyte increase or other progression criteria arise.[11][5]
• Use chemotherapy, immunotherapy, targeted therapies, glucocorticoids, radiotherapy, splenectomy, transplantation and supportive transfusion, antibacterial or antifungal treatment according to clinical indications and specialist recommendations.[10][11][15]
• Refer seriously ill patients or those requiring intensive treatment, complex diagnosis, management of severe complications, radiotherapy, splenectomy, transplantation assessment or palliative care to appropriate hospital-level services.[22][11]
• Maintain continuity after discharge through a documented management plan shared with the family doctor and district or municipal haematologist, including diagnosis, test results, treatment and follow-up recommendations.[14]
• Support specialised inpatient delivery with multidisciplinary staff, including haematologists, laboratory and imaging specialists, surgeons, nurses and laboratory technicians, alongside laboratory, imaging, bone-marrow, immunophenotyping and coagulation-testing capacity.[23][24]
• Apply governance through Ministry of Health, Labour and Social Protection expert and approval structures, including the relevant oncology, radiotherapy, haematology, blood-transfusion, medicines and insurance bodies.[25]
• Monitor implementation using clinical surveillance schedules, treatment-response criteria, three percentage indicators for treatment coverage and maintenance-related recurrence reduction, and a standardised criteria-based medical audit form.[26][4][27][28]
• Review patients in complete remission with blood counts every three months during the first two years, every six months during the next three years and annually thereafter; undertake more frequent monitoring during chemotherapy and for treatment-related autoimmune or infectious complications.[6][13]
• Use recommendation-strength and evidence-level classifications to distinguish standards, recommendations and options, and to relate recommendation grades to the quality of evidence.[29][30]
• Ensure traceability, validation and compatibility safeguards for blood components, including documented product identification and exceptional decision-making procedures for life-threatening transfusion circumstances.[31][32][33]

Monitoring & Evaluation

Monitoring is principally clinical and laboratory-based, supported by protocol implementation indicators, a criteria-based medical audit, discharge documentation, treatment-response criteria and blood-component quality controls. The available extracts do not define a unified programme-level reporting, surveillance or accountability system.[2][4][27][29]

• Monitor patients managed without immediate treatment through clinical and haematological review every three months, with treatment initiated or reconsidered when complications or disease progression arise.[11][5]
• Conduct haematologist-led follow-up to supervise prescribed treatment and identify relapse early, including joint review every three months.[6]
• Perform a complete blood count with reticulocytes and platelets every three months during the first two years of complete remission, every six months over the subsequent three years, and annually after five years.[18][6]
• Undertake complete blood counts weekly during systematic chemotherapy and monthly during subsequent surveillance, or according to the stability of haematological indicators.[13]
• Monitor patients not requiring specific treatment initially with peripheral-blood analysis monthly or every two months; a continuing rise in leucocytosis and lymphocytosis supports diagnostic confirmation.[12][34]
• Assess treatment eligibility and disease progression through constitutional symptoms, progressive or refractory anaemia or thrombocytopenia, tumour burden, organ enlargement, infections and lymphocyte-doubling time.[11]
• Use CD38 and ZAP70, cytogenetic abnormalities including del(17p), del(11q), trisomy 12, del(13q) and TP53 mutation, and selected immunogenetic markers for prognostic assessment. Cytogenetic examination may be deferred for patients not requiring treatment.[19][20][21]
• Assess response using International Working Group criteria covering lymph-node, liver and spleen enlargement, lymphocyte count, marrow involvement, platelet count, haemoglobin and neutrophil count. Complete remission, partial remission and progression are defined against specified clinical and haematological thresholds.[26][35]
• Monitor treatment safety through blood counts before further chemotherapy, deferring treatment for one week when neutrophils are below 1.0 × 10⁹/L or platelets below 75 × 10⁹/L, and monitor for cytomegalovirus reactivation during alemtuzumab treatment.[36]
• Monitor infusion-related reactions, including cytokine-release syndrome, during anti-CD20 monoclonal-antibody administration, and adjust or continue targeted therapies according to progression, adverse effects and tolerability.[37][38]
• Document discharge arrangements through a mandatory summary containing diagnosis, investigation results, treatment, patient advice and recommendations for family doctors and district or municipal haematologists.[14]
• Measure implementation through three percentage indicators concerning primary treatment and treatment of clinically and haematologically active disease, calculated from numbers of treated or registered patients during the preceding year.[4]
• Apply a standardised criteria-based medical audit form recording institutional and patient details, admission and referral routes, transfers, disease stage, diagnostics, specialist input, comorbidities, emergency care, risk status and treatment initiation.[27][28][39]
• Record clinical-monitoring compliance, treatment outcome, rehabilitation, discharge criteria, follow-up and final status. Classify outcomes as complete remission, partial remission, no effect, progression, complications or unknown.[29]
• Maintain blood-component traceability and validation records, including producer and unique identification, blood-group characteristics, production and expiry dates, storage conditions and validation status; assess specified component-quality parameters.[31][40][41][32][42][43]

Costing & Financing

No extract provides explicit monetary costs, budgets, allocations, financing sources, resource-mobilisation arrangements, funding gaps or economic assumptions, so no quantified costing can be consolidated.[3][11][24][27]

• Identify human and material resource requirements across primary care, specialised outpatient services, general hospitals and specialised hospital care, without attaching financial values.[2][23]
• Provide specialised inpatient capacity through haematologists, laboratory and imaging specialists, surgeons, nurses, technicians and functional-diagnostics staff, alongside laboratory, imaging, bone-marrow, immunophenotyping and coagulation-testing infrastructure.[24]
• Make available diagnostic resources including blood counts, marrow aspiration and biopsy, flow-cytometry immunophenotyping, pathology, imaging, microbiology and cytogenetic or molecular testing according to clinical need.[20][21]
• Supply treatment resources including antitumour medicines, monoclonal antibodies, antibacterial, antifungal and antiviral medicines, glucocorticoids, haematopoietic growth factors, transfusion products and supportive therapies.[16][24][4]
• Strengthen access to cytoreductive medicines and blood components, including erythrocyte and platelet concentrates and fresh frozen plasma, and identify allogeneic haematopoietic stem-cell transplantation as a potentially curative resource for eligible patients.[27]
• Require blood-component preparation, labelling, storage, validation and compatibility processes, including alternative-component arrangements for exceptional transfusion circumstances, but specify no associated costs.[31][44][33][45]